Immune checkpoint inhibitors caused changes to immune cells in the cerebrospinal fluid of treated patients and generated promising results in a phase II clinical trial.
- In patients with Alzheimer’s disease, amyloid-beta protein fragments accumulate in the tissue and blood vessels of the brain
- Very slow spontaneous vessel pulsations drive the clearance of substances from the brain
- Targeting and improving this process may help to prevent or treat amyloid-beta accumulation
Susanne van Veluw, PhD
If we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
Department of Neurology, Massachusetts General Hospital
BOSTON – In patients with Alzheimer’s disease, amyloid-beta protein fragments accumulate in the tissue and blood vessels of the brain, likely due to a faulty clearance mechanism. In experiments conducted in mice, investigators at Massachusetts General Hospital (MGH) have found that very slow spontaneous vessel pulsations – also known as ‘vasomotion’ – drive the clearance of substances from the brain, indicating that targeting and improving this process may help to prevent or treat amyloid-beta accumulation.
In their study published in Neuron, the researchers injected a fluorescently labeled carbohydrate called dextran into the brains of awake mice, and they conducted imaging tests to follow its clearance. Their experiments revealed that vasomotion was critical for clearing dextran from the brain and stimulating an increase of the amplitude of these vessel pulsations could increase clearance. Also, in mice with cerebral amyloid angiopathy, a condition that causes amyloid-beta to build up in the walls of the brain’s blood vessels, vessel pulsations were hindered and clearance rates were reduced.
“We were able to show for the first time that large dilations and contractions of vessels that happen spontaneously at an ultra-low frequency are a major driving force to clear waste products from the brain,” said lead author Susanne van Veluw, PhD, an investigator in the department of Neurology at MGH. “Our findings highlight the importance of the vasculature in the pathophysiology of Alzheimer’s disease. If we direct therapeutic strategies towards promoting healthy vasculature and therefore improve clearance of amyloid-beta from the brain, we may be able to prevent or delay the onset of Alzheimer’s disease in the future.”
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 the MGH was once again named #2 in the nation by U.S. News & World Report in its list of "America’s Best Hospitals."
- Press Release
- Oct | 19 | 2021
In pregnant women with COVID-19, sex of fetus may influence maternal and placental immune response and neonatal immune protection
The placentas of male and female fetuses respond very differently when a mother is infected with SARS-CoV-2 during pregnancy. Male placentas have significantly increased immune activation, and males receive significantly fewer anti-COVID antibodies from their mothers.
- Press Release
- Oct | 15 | 2021
‘Superhuman, but never enough’: Essay details inequities experienced by Black women physicians in the United States
A long history of discrimination against Black women physicians persists and contributes to their underrepresentation in medicine, argue physician-scientist Fatima Cody Stanford and her coauthors.
- Press Release
- Oct | 14 | 2021
Increasing moderate-to-vigorous physical activity by 17 minutes per day, adding 54 minutes of walking per day, or reducing 249 minutes of sedentary time per day corresponded to a 5% higher peak oxygen uptake during exercise.
- Oct | 11 | 2021
New research published in PNAS that was led by investigators at Massachusetts General Hospital (MGH) and the University of Geneva (UNIGE) provides insights on why some types of colorectal cancer don’t respond to immune checkpoint inhibitors and offers a strategy to overcome their resistance.
- Press Release
- Sep | 21 | 2021
Investigational drug SLS-005 (Trehalose) receives “May Proceed” notice and Central IRB approval for the HEALEY ALS Platform Trial
The Sean M. Healey & AMG Center for ALS at MGH received approval to proceed with adding SLS-005 (Trehalose) as an additional regimen in the HEALEY ALS Platform Trial.